Charles Craddock is Professor of Haemato-oncology at the University of Birmingham and the Academic Director of the Centre for Clinical Haematology at the Queen Elizabeth Hospital. He trained in haematology at the Hammersmith Hospital in London, the Institute of Molecular Medicine at the University of Oxford, and the University of Washington in Seattle, USA. Charlie is the Co-Founder of Cure Leukaemia.
Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He was elected President of the British Society Of Haematology in 2017. He led the development of the £24 million Birmingham Institute of Translational Medicine, which opened in 2015 and in 2017 oversaw the £3.4m expansion of the Centre for Clinical Haematology at the Queen Elizabeth Hospital.
Professor Craddock’s main research interests include the development of novel drug and transplant therapies in myeloid leukemias and he leads the UK Haemato-oncology Trials Acceleration Programme.
He pioneered the development of a UK stem cell transplant trials network, IMPACT, which was launched in 2017. Professor Craddock was awarded the CBE for services to medicine and medical research in the 2016 New Years Honours list.
How funds raised for Cure Leukaemia help save lives